Atorvastatin
- Generic Name
- Atorvastatin
- Brand Names
- Atorvaliq, Caduet, Lipitor, Lypqozet
- Drug Type
- Small Molecule
- Chemical Formula
- C33H35FN2O5
- CAS Number
- 134523-00-5
- Unique Ingredient Identifier
- A0JWA85V8F
- Background
Atorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competitively inhibit the enzyme hydroxymethylg...
- Indication
Atorvastatin is indicated for the treatment of several types of dyslipidemias, including primary hyperlipidemia and mixed dyslipidemia in adults, hypertriglyceridemia, primary dysbetalipoproteinemia, homozygous familial hypercholesterolemia, and heterozygous familial hypercholesterolemia in adolescent patients with failed dietary modifications.
...
- Associated Conditions
- Anginal Pain, Cardiovascular Complications, Cardiovascular Disease (CVD), Coronary Artery Disease (CAD), Coronary artery thrombosis, Dysbetalipoproteinemia, Fredrickson Type III lipidemia, Heterozygous Familial Hypercholesterolemia (HeFH), High Cholesterol, Homozygous Familial Hypercholesterolaemia (HoFH), Hospitalizations, Hypertension, Essential Hypertension, Hypertriglyceridemias, Mixed Dyslipidemias, Mixed Hyperlipidemia, Myocardial Infarction, Non-familial hypercholesterolemia, Nonfatal Myocardial Infarction, Postoperative Thromboembolism, Primary Hypercholesterolemia, Stroke, Thrombosis, Transient Ischemic Attack, Elevation of serum triglyceride levels, Heterozygous familial hyperlipidemia, Non-familial hyperlipidemia, Primary Hyperlipidemia, Revascularization procedures
- Associated Therapies
- -
Evaluation of Efficacy and Safety of Omacor, Co-Administered With Atorvastatin, in Subjects With Hypertriglyceridemia
- Conditions
- Interventions
- First Posted Date
- 2007-02-14
- Last Posted Date
- 2017-02-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 245
- Registration Number
- NCT00435045
An Open Labeled Pilot Study of Atorvastatin in Systemic Lupus Erythematosus
- Conditions
- First Posted Date
- 2007-02-07
- Last Posted Date
- 2007-03-20
- Lead Sponsor
- Buddhist Tzu Chi General Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT00432354
- Locations
- 🇨🇳
Dalin Tzu Chi General Hospital, Chia-yi, Taiwan
🇨🇳Buddhist Dalin Tzu Chi General Hospital, Chia-Yi, Taiwan
Study of Asian Patients With Hypercholesterolaemia in the UK - Rosuvastatin 5mg Versus Atorvastatin 10mg
- Conditions
- Interventions
- First Posted Date
- 2007-01-29
- Last Posted Date
- 2010-12-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 55
- Registration Number
- NCT00427960
- Locations
- 🇬🇧
Research Site, Newcastle, United Kingdom
🇬🇧Research SIte, Slough, United Kingdom
Ezetimibe and Atorvastatin vs. Atorvastatin in Patients Age 65 and Older at High Risk for Coronary Heart Disease (CHD)(0653-112)
- Conditions
- Interventions
- First Posted Date
- 2007-01-05
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1053
- Registration Number
- NCT00418834
Investigations on Differences in Atorvastatin Metabolites Ratios as a Diagnostic Tool in Detecting Atorvastatin Induced Myotoxicity
- First Posted Date
- 2006-12-21
- Last Posted Date
- 2014-12-03
- Lead Sponsor
- University of Oslo School of Pharmacy
- Target Recruit Count
- 53
- Registration Number
- NCT00414531
- Locations
- 🇳🇴
Rikshospitalet-Radiumhospitalet HF, Lipid clinic, Oslo, Norway
Atorvastatin to Prevent Avascular Necrosis of Bone in Steroid Treated Exacerbated Systemic Lupus Erythematosus
- Conditions
- Interventions
- First Posted Date
- 2006-12-19
- Last Posted Date
- 2018-11-23
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 43
- Registration Number
- NCT00412841
- Locations
- 🇺🇸
The New York University Hospital For Joint Diseases, New York, New York, United States
Study To Determine The Effects Of Doses Of Relacatib On The Metabolism Of Acetaminophen, Ibuprofen And Atorvastatin
- Conditions
- Interventions
- First Posted Date
- 2006-12-13
- Last Posted Date
- 2017-10-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 32
- Registration Number
- NCT00411190
- Locations
- 🇧🇪
GSK Investigational Site, Liège, Belgium
ROMEO (Rosuvastatin in Metabolic syndrOme)
- First Posted Date
- 2006-11-03
- Last Posted Date
- 2011-07-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 258
- Registration Number
- NCT00395486
- Locations
- 🇰🇷
Research Site, Suwon, Korea, Republic of
Regulation of Lipoprotein Metabolism in Obese Men
- Conditions
- First Posted Date
- 2006-10-26
- Last Posted Date
- 2006-10-26
- Lead Sponsor
- The University of Western Australia
- Target Recruit Count
- 48
- Registration Number
- NCT00392717
- Locations
- 🇦🇺
Royal Perth Hospital, Perth, Western Australia, Australia
This Study Uses Ultrasound to Determine Whether Atorvastatin or Pravastatin Effects the Progression of Coronary Plaque.
- Conditions
- First Posted Date
- 2006-09-27
- Last Posted Date
- 2006-12-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 600
- Registration Number
- NCT00380939
- Locations
- 🇺🇸
Pfizer Investigational Site, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.